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Abstract
Taxane based chemotherapy is the standard of care treatment in castration resistant prostate cancer (CRPC). There
is convincing evidence that taxane therapy affects androgen receptor (AR) but the exact mechanisms have to be
further elucidated. Our studies identified c-jun as a crucial key player which interacts with AR and thus determines
the outcome of the taxane therapy given. Docetaxel (Doc) and paclitaxel (Pac) agents showed different effects on
LNCaP and LNb4 evidenced by alteration in the protein and mRNA levels of c-jun, AR and PSA. Docetaxel-induced
phophorylation of c-jun occurred before JNK phosphorylation which suggests that c-jun phosphorylation is
independent of JNK pathways in prostate cancer cells. A xenograft study showed that mice treated with Pac and
bicalutamide showed worse outcome supporting our hypothesis that upregulation of c-jun might act as a potent
antiapoptotic factor. We observed in our in vitro studies an inverse regulation of PSA- and AR-mRNA levels in Doc
treated LNb4 cells. This was also seen for kallikrein 2 (KLK 2) which followed the same pattern. Given the fact that
response to taxane therapy is measured by PSA decrease we have to consider that this might not reflect the true
activity of AR in CRPC patients.
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Introduction
The treatment options for patients with castration resistant
prostate cancer (CRPC) are still limited. Although new
promising drugs like CYP17A1 inhibitor arbiraterone and
MDV3100 have entered the market, taxane based
chemotherapy is still considered worldwide the most important
cornerstone of treatment when androgen deprivation therapy
(ADT) has failed [1-4]. Besides the classic taxanes, Docetaxel
and Paclitaxel, Cabazitaxel is used as chemotherapeutic agent
in the treatment of CRPC patients, the latter mostly to treat
patients with Doc resistant disease [5].
Taxanes arrest cells in the G2-M phase by hyperstabilization
of the microtubules prompting the cells to cell death [6].
Besides this well described effect in tumor cells there is
convincing evidence that taxane therapy also interferes with
androgen receptor (AR) in prostate cancer cells [7-11]. Our
group has identified c-jun as an important key player in this
interaction between AR and taxanes which affects the outcome
of treatment in the castration resistant status of prostate cancer
cells.
Transcription factor c-jun is a proto-oncogene and belongs to
the AP-1 family which consists of the jun, fos and ATF-2
subfamilies [12,13]. AP-1 proteins homo- or heterodimerize
before binding to their DNA target site. The AP-1 proteins are
multifunctional and involved in regulating stress response
signals, cell growth and apoptosis [12]. Nevertheless, there are
data which strongly suggest that c-jun is a growth promoter and
proto-oncogene [14,15]. Shemshedini and coworkers showed
that, similar to what observed with other AR coactivators, c-jun
can mediate AR N-to-C interaction to enhance DNA binding
[16,17]. Furthermore, phosphorylated c-jun is frequently
overexpressed in human cancers [18,19] and has been linked
to invasive properties of prostate and breast cancer [18,20,21].
However, the role of c-jun activation and possible interaction
with AR in the cell fate after exposure to Doc is part of a
complex network and remains to be elucidated. This study was
carried out to investigate the consequence of interaction of c-
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jun and AR in taxane treatment of castration resistant prostate
cancer cells. To optimize the efficacy of chemotherapy with
taxanes we need to identify a specific molecule or pathway
which may confer response or resistance. In the present study
we sought to examine the effect of taxanes as single agent or
in combination with bicalutamide on AR and its cofactor c-jun in
vitro and in vivo.
Materials and Methods  
Cell lines and Reagents
The human prostate cancer cell lines LNCaP and PC-3 were
obtained  from the American Type Culture Collection (ATCC,
Manassass, VA). LNb4 cells were generated in our laboratory
from LNCaP cells exposed to bicalutamide (5 µM in serum
reduced to 5%). Cells were cultured in RPMI (LNCaP) and
Hams-F12 (PC-3) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin (Life Technologies,
Paisley, UK). Cells were treated with Docetaxel (Taxotere®,
Sanofi Aventis) and Paclitaxel (Paclitaxel®, Actavis,
Hafnarfjordeur, Iceland) in the concentration stated in each
figure. Dihydrotestosterone (DHT) was purchased from
Steraloids Inc. (Newport, RI) and bicalutamide from
AstraZeneca (London, UK). All Western blot reagents were
purchased from Invitrogen (Carlsbad, CA, USA) except JNK
inhibitor XIV SR 3306 (Calbiochem, Darmstadt, Germany).
Transfection and small interfering RNA (siRNA)
Transient transfections with c-jun, c-jun mutant (c-jun
Ala63/73) and AR plasmids (all kindly provided by Shao-Yong
Chen, Harvard Medical School) in PC-3 prostate cancer cells
were performed using FuGENE 6 (Roche Diagnostics,
Mannheim, Germany) as recommended by the manufacturer.
The c-jun mutant (c-jun Ala63/73), herein referred as junA,
used in experiments carries a mutation at the serine site 63/73
(Ala63/73) which is the major target of phophorylation by stress
stimuli. For siRNA experiments, PC-3 and LNCaP cells were
transfected for 48 hours with 100 nM siRNA c-jun or non-
targeting siRNA (Cell Signaling Technology, Danvers, MA,
USA). Transfection was performed using X-tremeGENE siRNA
transfection reagent (Roche Diagnostics) according to
manufacturers instruction.
Proliferation
Cell viability was defined by trypan blue exclusion (Sigma-
Aldrich, St Louis, MO, USA). PC-3, LNCaP and LNb4 cells
were seeded in 24-well plates at a density of 25,000 cells per
well. After 24 and 48 hours treatment with Doc or DMSO
(Sigma-Aldrich) at the concentrations indicated floating and
attached cells were collected by trypsinization. Equal portions
of cell suspensions and 0.4% trypan blue were mixed, and the
number of viable, trypan blue-excluding cells were counted by
using a hemacytometer. The percentage of viable cells was
expressed per 100 of the total cells (mean ± SD). transfected
PC-3 cells were further evaluated by MTS assay. After 48
hours of transfection cells were exposed to Doc or remained
untreated for further 48 hours. After incubation at 37 °C in 5%
CO2 for 4 hours, the number of living cells was measured using
an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Celltiter 96
Aqueous One-solution Cell Proliferation assay, Promega,
Madison, WI, USA) according to the manufacturers
instructions. Absorbance was measured at 490 nm using a
multiwell plate reader (Model 680, Bio-Rad, Richmond, CA,
USA), with wells containing only medium serving as blank
controls.
Flow cytometry for cell cycle and apoptosis analyses
Cell cycle distribution was analyzed by flow cytometry.
Briefly, transfected cells were treated with Doc for 48 hours and
were fixed and stained with propidium iodide for 40 min. The
viable cells were gated, and DNA content of at least 10 000
labeled cells was quantified with a fluorescence-activated cell
sorter. Apoptosis was determined by Annexin V conjugated
with fluorescein isothiocyanate (FITC) and 7-AAD staining (BD
Pharmingen of BD Bioscience, San Jose, CA, USA). Cells
were treated with Doc for 48 and 72 hours and stained cells
were subjected to flow cytometric analysis on a FACSCalibur 
(BD Bioscience, San Jose, CA, USA) instrument. Data
presented are obtained from two independent experiments in
duplicates and were analyzed using FCS Express software
(DeNovo Software, Los Angeles, CA, USA).
Western Blot analysis and Immunoprecipitation
For Western blot analysis total protein was extracted using
radioimmunoprecipitation assay (RIPA) buffer (50 mmol/L Tris-
HCl, 150 mM NaCl, 20 mM EDTA, 1% NP40, 0.1%  SDS, 1
mM Na3VO4, 1 mM NaF and 1 mM
phenylmethylsulfonylfluoride ) supplemented with the protease
inhibitor cocktail Complete Mini ( Roche, Mannheim, Germany).
Total protein concentration was measured using BCA protein
assay (Pierce, Rockford, IL). Protein samples (20-30 µg) were
loaded on 4-12 % SDS-PAGE and transferred to a
nitrocellulose membrane Bio-Rad assay (Bio-Rad, Hercules,
CA, USA) and subjected to electrophoretic analysis and
blotting. Membranes were probed overnight at 4 °C with the
following primary antibodies: anti-AR (441 and N-20), anti-c-
jun, anti-p-cjun (ser 63/73), and  anti-β-actin, all purchased
from Santa Cruz ( Santa Cruz Biotechnology,CA), anti-PSA
(Dako, Glostrup, Denmark ), p-JNK from Cell Signaling
Technology (Beverly, MA). Secondary antibodies (IRDye 680,
IRdye 800) were obtained from Li-Cor Biotechnology
(Nebraska, USA ) and proteins detected by Odyssey® Infrared
Imaging System.
For immunoprecipitation cells were treated as indicated and
harvested in lysis buffer. Cell lysates were homogenized,
protein content measured and 500 μg of precleared protein
was incubated with anti-AR antibody at 4°C overnight with
continuous agitation. Equal amounts of mouse IgG was used
as negative control. Protein G beads (Pierce, Rockford, IL,
USA) were then added to each sample and incubated at 4 °C
for 2 hours. Samples were then centrifuged at 2000 x g 2 min
and Laemmli sample buffer (30 μl) without β-
mercaptoethanol added and the mixture incubated at 65°C for
15 minutes to elute bound proteins. Eluate fractions were
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centrifuged at 2000 x g, 1μl of β-mercaptoethanol was added
and samples subjected to Western blotting as described above.
Protein expression was evaluated relative to β-actin expression
by Densitometric analysis.
Real-time Quantitative PCR Analysis  
Total RNA was isolated from the LNCaP and LNb4 cells
using RNeasy Mini Kit (Qiagen, West Sussex, UK) following
the manufacturers protocol and treated with RNase-free DNase
(DNase I; Amersham Pharmacia Biotech, Sollentuna, Sweden)
to remove potential genomic DNA contaminants. Each cDNA
was synthesized by reverse transcription from 1 μg of total
RNA using the StrataScript First-Strand Synthesis System and
random hexamer primers (Stratagene; AH diagnostics,
Stockholm, Sweden). Real-time PCR was performed with
SYBR Green QPCR master mix ( iScript from BioRad)  in a MX
3000P detection system (Stratagene) with an initiation step at
95°C for 10 minutes followed by 40 cycles at 95°C for 30
seconds, 56°C for 1 minute and 72°C for 1 minute.
The following primers for each gene were used: PSA (F5'-
AGGCCTTCCCTGTACACCAA-3' and R5'-
GTCTTGGCCTGGTCATTTCC-3'), AR (F 5'-
GTACCTGTCAGCCCCTGAAC-3' and R5' GGAGAGCTGCT
TTCG- CTTAG-3'), GAPDH (5' -CGA CCA CTT TGT CAA GCT
CA-3' and 5'-AGG GGT CTA CAT GGCAACTG-3'), c-jun (F 5´-
GCATGAGGAACCGCA- TCGCTGCCTCCAAGT-3 and R5
´GCGACCAAGTCCTTCCCACTCGTGCA- CACT-3'), NKX3.1
(F 5´- GTACCTGTCGGCCCCTGAACG-3´ and R5´-GCT-
GTTA TACACGGAGACCAGG-3´), c-Myc (F 5´-
GGCGGGCACTTTGCACTGGA-3´and R5´-
TCGCGGGAGGCTGCTGGTTT-3´), KLK2 ( F 5´-
AGATGAAGACTCC-AGCCAT-3´ and R 5´-
GATACCTTGAAGCACACCA -3´), β-actin (F 5´-CGTGG-
GGCGCCCCAG -3´ and R 5´-
TTGGCCTTGGGGTTCAGGGGG -3´).
The mRNA amount was determined by using the
comparative CT method. Samples were analyzed in triplicates
and the data compared with the expression of mRNA in non-
treated control which was set as a reference value.
Animals and tumor inoculation
Four to six weeks old NMRI male Nude mice from Taconic
Europe (Lille Skensved, Denmark) were used in the
experiment. The xenograft model was carried out according to
the protocol specifically approved by the Ethics committee of
Lund university (approval number M 239-10). Mice were kept
according to the guidelines given by the Malmö-Lund Ethical
Committee. LNCaP cells (2x106 cells) were injected
subcutaneously into both flanks resulting in two tumors per
mouse. After tumors have developed surgical castration was
performed. The animals were assigned into 6 groups: mice
were treated with vehicle, Doc, Pac or bicalutamide as a single
agent and Doc or Pac combined with bicalutamide. Drugs were
administered intraperitoneally (i.p.) (à 20 mg/kg) in 100 µl
volume once a week for 5 weeks except for bicalutamide which
was administered twice a week. At the time point designated
week 0, treatment was initiated and mice were sacrificed one
week after the last treatment. Tumors were harvested, fixed in
formalin and paraffin embedded for immunohistochemical
analysis.
Immunohistochemistry
Dissected xenograft tumors were fixed in 4%
paraformaldehyde and thereafter embedded in paraffin.
Four µm thick sections were deparaffinized, rehydrated and
microwave treated for 10 min in high pH target retrieval solution
(Dako, Glostrup, Denmark) before being processed in
automatic Techmate 500 immunohistochemistry staining
machine (Dako) using antibodies against AR, c-jun, p-cjun, and
Ki-67 (Dako). DAB (3,3'-diaminobenzidine) was used as a
chromogenic substrate and slides were counterstained with
hematoxylin. The specimens were viewed with an Olympus AX
70 microscope at a magnification of x 10. An arbitrary
semiquantitative scoring was applied to evaluate the staining
signals and scored in three categories; negative staining (0),
weak but detectable staining of some or all cells (1), moderate
staining (2) or strong staining (3). At least two sections per
tumor were determined and the scores were representative for
at least 70% of the area of tissue analyzed.  
Sub-cellular fractionation
Cellular fractionation was performed according to the
protocol supplied with the NE-PER nuclear and cytoplasmic
extraction reagents (Pierce, Rockford, IL). LNCaP cells were
exposed to Doc or Pac for 6, 24 and 48 hours or remained
untreated. Fractions were boiled with SDS sample buffer,
subjected to SDS-PAGE, and transferred to a nitrocellulose
membrane and probed as indicated with primary antibodies to
AR, β-actin or lamin A, all from Santa Cruz, followed by
secondary antibodies (IRDye 680,  IRdye 800) which were
obtained from Li-Cor Biotechnology (Nebraska, USA). Proteins
were detected by Odyssey® Infrared Imaging System.
Statistical Analysis
Results were obtained from at least three experiments
performed and are expressed as the mean ± SD. Statistical
significance was determined with unpaired Student's t-test.
Values of p < 0.05 were considered significant.
Results
c-jun overexpression induced resistance to Doc
treatment
The function of c-jun as a transcription factor related to
proliferation has been reported in prostate cancer before [22].
To investigate the impact of c-jun on Doc treated prostate
cancer cells, experiments were carried out in LNCaP, LNb4
and PC-3 cells. We observed that LNCaP cells treated with
Doc were more resistant to the treatment at indicated time
points compared to PC-3 cells (30 % vs 9%, p=0.003) (Figure
1A). Although we did not detect a statistically significant
difference between LNCaP and LNb4 we could see a tendency
that long term treatment with bicalutamide increases resistance
(Figure 1A). Furthermore apoptosis analysis was performed by
Taxane Therapy in Prostate Cancer
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e79573
using Annexin V/7AAD confirming less apoptosis in LNb4 cells
exposed to Doc compared to parental LNCaP cells
(Figure 1B). To examine whether c-jun is involved in the
response to Doc therapy, PC-3 cells were transfected with c-
jun, c-jun mutant (junA) and co-transfected with AR (AR/cjun,
AR/junA, respectively) plasmids and MTS assay carried out.
PC-3 cells transfected with junA showed a statistically
significant increase (p=0.01, junA vs control) in cell proliferation
(Figure 1C) whereas transfection with AR decreased cell
viability comparable to Doc treated control cells. Although there
was no statistically significant difference between Doc treated
control cells and c-jun transfected PC-3 cells there was a clear
tendency to increased viability in the latter. Interestingly, co-
tranfection of AR in PC-3 cells overexpressing of c-jun or junA
did not abrogate this effect on proliferation (Figure 1C)
suggesting a role of c-jun as a potent antiapoptotic factor. Cell
cycle analysis was then carried out and displayed cell arrest in
G2-M phase in Doc treated PC-3 cells (Figure 1D). We
observed that PC-3 cells transfected with AR or junA showed a
similar trend with a marked decrease of percentage of cells in
G2-M phase (18,6% and 19,9%, respectively), while S phase
was increased (43,4% and 43,5%, respectively), suggesting
that the phosphorylation of c-jun plays a crucial role in cell
response to Doc (Figure 1D).
We next examined the protein expression in the transfected
PC-3 cells. Western blotting analysis showed a marked
increase in AR protein in cells co-transfected with AR/cjun
compared to cells transfected with AR alone or AR/junA (Figure
1E). These results suggest that the interaction between AR and
c-jun is dependent on the available phophorylation site 63/73.
To further evaluate the effect of taxane agents on endogenous
c-jun and AR immunoprecipitation was performed in LNCaP
and LNb4. We found an interaction between AR and c-jun in
both cell types, which was enhanced by Doc and Pac treatment
(Figure 1F). These findings confirm that there is a physical
interaction between c-jun and AR which regulates the effect of
taxane therapy in PC cells.
Effects of c-jun siRNA on Doc response
To investigate whether c-jun downregulation can alter PC
cell response to Doc we transfected PC-3 and LNCaP cells
with siRNA or nontargeted siRNA, which served as a control
(Figure 2A). Cells were exposed to Doc for 24 or 48 hours and
subjected to MTS assay. c-jun was significantly downregulated
although not completely diminished in both cell lines (Figure
2A). LNCaP cells silenced with siRNA showed a clear
decrease in viability after 24 hours to Doc exposure compared
to parental LNCaP cells (p=0.002). In PC-3 cells we did not
observe a significant change in cell viability at the same time
point. After 48 hours the effect of c-jun silencing decreased and
cells recovered as shown in Figure 2B.
Taxane-induced p-cjun expression is independent on
JNK pathway in PC cells
It has been reported that Doc chemotherapy induces its
effect through selectively activating JNK in cancer cells [23].
Once activated, JNK phosphorylates and activates a number of
transcription factors such as c-jun. To address this question we
analyzed whether JNK signaling pathway has a role in Doc-
induced prostate cancer cell death. PC-3 and LNCaP cells
were treated with 500 nM of JNK inhibitor for 2 or 8 hours,
whereas Doc and Pac treated cells performed in time points 2,
4, 8 and 24 hours. As shown in Figure 3A c-jun
phosphorylation was induced 2 hours after exposure to Doc in
PC-3 cells, while JNK phosphorylation appeared 24 hours after
exposure in PC-3 cells only (Figure 3A). In LNCaP cells
exposed to Doc no marked changes in JNK phophorylation
was observed at any time point of drug treatment (Figure 3B).
This suggests that the JNK activation may be a secondary
effect of Doc treatment and c-jun phosphorylation is a primary
target of Doc. Especially in AR expressing LNCaP cells, a
direct interaction with AR that cause rapid induction of c-jun
phosphorylation cannot be excluded. Furthermore, similar
results were obtained in the aforementioned cells exposed to
Pac (figure not shown). It is worth mentioning that a basal level
of p-cjun in non-treated cells was expressed in both cell lines.
Taxane agents alter protein levels of AR and PSA
Further experiments were exclusively carried out in LNCaP
and LNb4 cells only. Based on our above result we further
examined how taxane therapy affects the expression of AR
regulated genes such as PSA on protein level. We observed a
concomitant increase of AR and PSA protein levels in Doc
treated LNCaP cells (p=0.01, Doc 24 vs control) (Figure 4A).
However, in Pac treated LNCaP cells a gradual decrease of AR
protein was seen concomitantly with PSA level after 48 hours
(Figure 4A). Interestingly, the increase of AR protein level in
LNb4 cells was more pronounced by Doc treatment, whereas
PSA protein level was clearly decreased after 48 hours
(p=0.02, Doc 24 vs Doc 48). Exposure of LNb4 cells to Pac led
to a markedly decrease in AR and PSA protein expression
(Figure 4B). Expression of p-cjun differed in LNCaP and LNb4
(Figure 4C,D). In LNCaP cells Doc treatment increased p-cjun
expression gradually (p=0.04, Doc 6 vs Doc 48), whereas in
Pac treated cells an increase at 24 hours was seen, which was
followed by a marked decrease at 48 hours (Figure 4C).
However, in LNb4 cells Pac treatment resulted in a time-
dependent induction of p-cjun, whereas Doc treatment failed to
do so (Figure 4D). No marked changes in c-jun levels were
observed in both cell lines and under all conditions examined.
Effect of taxane treatment on c-jun and AR mRNA
expression
To investigate the RNA changes due to taxane treatment,
QRT-PCR was carried out in LNCaP and LNb4 cells. Cells
were treated as indicated in Figure 5. Although we observed an
initial induction of AR- and PSA mRNA in Doc treated LNCaP
cells, this did not occur in Pac treatment. Interestingly, LNb4
cells showed a continuous increase of AR mRNA expression in
a time dependent manner when treated with Doc, whereas
PSA mRNA was negatively correlated to AR mRNA expression
(Figure 5A). There was a statistically significant difference in
the AR and PSA mRNA level at 24 and 48 hours of exposure to
Doc (p=0.05 and p=0.003, respectively). However, in Pac
treated LNb4 cells we observed an initial induction of AR and
PSA mRNA which decreased to a significant level after 48
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Figure 1.  Cell proliferation, apoptosis, cell cycle analysis and protein analysis.  (A) Cell viability examined by trypan blue
exclusion in LNCaP (LN), LNb4 and PC-3 cells. (B) Determination of apoptosis by flow cytometry. After treatment of cells with Doc,
the extent of apoptosis was assessed by annexin V/7AAD assay. (C) MTS assay in PC-3 cells transfected as indicated in figure and
treated 48 hours with 5 nM Doc. (D) Graphs from flow cytometry in cells mentioned in (C) demonstrating cycling cell population
stained with propidium iodide. Cells were treated with Doc for 48 h or remained untreated and sorted into different stages of mitosis
by flow cytometry. (E) Western blotting analysis to show protein expression in transfected cells mentioned in (C). (F) Analysis of
protein-protein interaction determined by immunoprecipitation in the presence or absence of Doc or Pac in LN and LNb4 cells. Cells
were immunoprecipitated with anti-AR (441) antibody and membranes were probed with anti-c-jun antibody. For control, 20 µg of
the cell lysate was used as input and equal loading was confimed with AR antibody.
doi: 10.1371/journal.pone.0079573.g001
Taxane Therapy in Prostate Cancer
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hours. In contrast, c-jun mRNA expression increased
significantly in Pac treated LNb4 cells (p=0.03), which could not
be shown in Doc treated cells (Figure 5B). As expected KLK2
mRNA expression showed a similar pattern like PSA mRNA in
all cells treated. Further analyzes on c-myc and NKX3.1 was
performed as shown in Figure 5B. The results show no
significant trend in c-Myc mRNA expression regardless of
taxane used and time of treatment. Nevertheless we observed
an increased expression of NKX3.1 mRNA in all Doc treated
cells, while this was less pronounced in Pac treated cells
(Figure 5B).
To summarize our results show a clear correlation between
AR, c-jun and PSA in taxane treated cells. The outcome of the
Figure 2.  Determination of c-jun siRNA.  (A) Western
blotting analysis showing transfection efficiency of siRNA c-jun
in both PC-3 and LNCaP cells. (B) Cell proliferation in LNCaP
(upper panel) and PC-3 (lower panel) cells transfected with c-
jun siRNA or nontargeted (control) vector. Cells were treated
with Doc for 24 and 48 hours. LNCaP cells harbor c-jun siRNA
showed a significant decrease in proliferation (p=0.002) while
PC-3 cells were not affected.
doi: 10.1371/journal.pone.0079573.g002
treatment is dependent on the status of AR receptor and c-jun
mRNA expression and the taxane used.
Animal model
To assess the therapeutic response of the prostate cancer
cell line LNCaP in vivo we established an animal model as
indicated in Figure 5. Mice were treated with Doc or Pac as
single agent or in combination with bicalutamide. A statisitically
significant reduction in tumor size of mice treated with Doc
alone was shown (p=0.04, Doc vs ctr) (Figure 6A). In mice
treated with Pac a stabilization but no decrease in tumor
volume was observed (Figure 6A). There was no significant
difference observed between Doc treated mice and mice
receiving combined treatment with bicalutamide (Figure 6C).
Interestingly, tumors in mice treated with Pac and bicalutamide
tumors started to regrow after an initial stabilization (Figure
6C). There was a statistically significant tumor size reduction in
Doc/bic compared to Pac/bic treated mice (p=0.003).
We next examined the expression of c-jun, p-cjun, AR and
Ki67 proteins in the tumor tissues harvested to assess the
effect of drug treatment. There was a significant change in
nuclear AR levels in animals treated with Doc alone or Doc/bic
(Figure 6B and 6D, respectively). In both treatment groups
approximately 60% of the cell population displayed a
Figure 3.  Taxane-induced p-cjun expression is
independent on JNK.  Western blotting analysis of (A) PC-3
and (B) LNCaP cells exposed to Doc (5 nM) for up to 24 hours
or remained untreated (0). PC-3 and LNCap cells were seeded
in 24-well plates at a density of 50,000 cells per well and
treated with Doc and Pac or in combination with 500 nM of JNK
inhibitor (SB) as indicated.
doi: 10.1371/journal.pone.0079573.g003
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cytoplasmic translocation of AR, compared to mice in control
group (Figure 6B). In contrast, mice treated with Pac or
combination therapy the cytoplasmic translocation of AR was
less pronounced. However, the expression of p-cjun in tissues
from control animals displayed an intense staining, whereas we
observed that nuclear p-cjun was more distinct in Pac treated
mice compared to Doc treated animals where also a
cytoplasmic expression was found (Figure 6B). No significant
change in the pattern of c-jun expression was seen in control
and treated animals. Ki67 expression was more pronounced in
Pac treated mice which reflects the poor response of tumors to
this taxane in vivo.
To confirm the cytoplasmic translocation of AR by taxane
therapy in vitro, Western blotting experiments were performed
in LNCaP cells (Figure S1). In agreement with the in vivo data
we demonstrated that independent on the taxane used AR was
translocated to the cytoplasm. The translocation was more
pronounced in Doc treated cells (upper panel) compared to
Pac treated cells (lower panel), especially after 48 hours of
treatment.
Discussion
In this study, we elucidated the role of AR and its coactivator
c-jun in the PC cell response to taxane therapy. We have
shown that c-jun overexpression in PC-3 cells confers a
statistically significant higher resistance to Doc treatment
compared to cells co-transfected with AR/c-jun or AR alone.
LNCaP cells were more resistant to Doc in the presence or
absence of bicalutamide compared to PC-3 cells. Transfection
with mutant junA increased viability, suggesting that c-jun and
the phophorylation site 63/73 is a key regulator of cell response
to taxanes in PC. We have shown for the first time that Doc
and Pac treatment differently affects protein and mRNA levels
of AR and PSA in parental LNCaP and LNb4 cells. These
differences were reflected in tumor growth in the mouse model.
Results presented here provide evidence that the effect of
Figure 4.  Taxane altered AR, PSA and p-cjun protein level.  Western blotting analysis of the expression of AR and PSA in (A)
LNCaP and (B) LNb4 cells. Cells exposed to 5 nM of Doc, 5 nM of Pac or 10 nM of DHT for up to 48 hours or remained untreated.
The same lysates were used to analyse the expression of p-cjun and c-jun in (C) LNCaP and (D) LNb4 cells. Protein expression
levels were evaluated by densitometric analysis (lower panels).
doi: 10.1371/journal.pone.0079573.g004
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taxane treatment is strongly dependent on the c-jun and AR
status of the cell line used and on the drug used for treatment.
It is known that AP-1 transcription factor is multifunctional
and sometimes controversially discussed in literature [24]. c-jun
has been demonstrated to transduce a mitogenic response and
to promote cell growth as a single gene or in cooperation with
an activated ras gene [25,26]. Accordingly, we have found that
c-jun overexpression (mutant junA) confers resistance to PC-3
cells to Doc therapy. Interestingly, junA was found to be more
potent in preventing cell death compared with AR suggesting
that the phophorylation site 63/73 is crucial for the interaction
and stabilization of AR and c-jun complexes. This finding is in
line with previously reported studies indicating that c-jun may
act as an antiapoptotic factor rather than proapoptotic in
context with exposure to chemotherapeutic agents [14,27]. This
was also confirmed in our study by silencing of c-jun in LNCaP
Figure 5.  Quantitative real-time RT-PCR.  Expression of (A) AR and PSA and (B) c-jun, KLK2, NKX3.1 and c-Myc mRNA levels in
response to Doc or Pac was evaluated by quantitative real time PCR (qPCR). The relative mean mRNA expression level of AR
regulated genes was measured by quantitative real-time RT-PCR in triplicates.
doi: 10.1371/journal.pone.0079573.g005
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cells which resulted in a better cell response to Doc exposure
after 24 hour reflected by a decrease in cell viability. However,
silencing in PC-3 cells did not significantly inhibit cell growth
upon Doc therapy in this study which was also observed by
other groups. Choong et al. showed in their study a
downregulation on protein level for c-jun in PC-3 cells which did
not result in cell growth inhibition [28]. However, they could
show that the oligonucleotide Dz13, a DNA enzyme cleaving c-
jun mRNA, could effectively downregulate the target gene
resulting in a significant growth inhibiton. Interaction of AR and
c-jun has been shown by us and others [22,29], and this may
provide basis for the reduced sensitivity to Doc treatment
exhibited in LNCaP but also in LNb4 cells. Although other
authors have reported that the phosphorylation of c-jun by
taxane therapy in other cancer cells was induced by JNK
pathway, we could not observe this in this study. We found c-
jun phosphorylation to be an early event before JNK pathway is
activated and we have to speculate that c-jun activation occurs
through a yet undefined pathway independent on JNK or is
autophosphorylated.
The effects of taxane therapy on AR obtained in this study
was to some extent in line with previous reports [6,9,11,30],
however, their studies differ in terms of concentrations of
taxanes or in cell lines used for in vitro and in vivo experiments.
We have used PTEN negative LNCaP and LNb4 cells to
investigate the impact of Doc and Pac in a head to head study
in vitro and in vivo. The inverse correlation of AR and PSA
observed in Doc treated LNb4 cells was an important finding in
this study as response to chemotherapy in patients treated by
Doc therapy still relies on PSA measurements. This study
confirms also the results published by Kuroda et al., where
PSA as a suitable surrogate marker for response to Doc
treatment was critically discussed [31]. An explanation for this
finding might be that AR and c-jun protein interact and can
repress the androgenic induction of PSA gene as reported by
Sato and coworkers in parental LNCaP cells. They suggested
that this repression is regulated by the ratio of AR and c-jun
[32]. The fact that we could observe a clear difference between
Pac and Doc treated LNb4 cells underlines our hypothesis that
Figure 6.  Tumor growth graphs and immunohistochemical analysis of dissected tumors from NMRI-nude mice bearing
implanted LNCaP cells.  (A) Growth curve of mice treated with Doc or Pac alone, Doc vs ctr (p=0.04). (B) Corresponding
immunohistochemical staining of tumor tissue. (C) Growth curve of mice with combined treatment, Doc/bicalutamide (Bic) vs
Pac/Bic (p=0.003). (D) Corresponding immunohistochemical staining of tumor tissue. Note that p-cjun was differentially expressed in
mice treated with Doc and Pac. Ki67 expression was higher in Pac compared to Doc treated mice.
doi: 10.1371/journal.pone.0079573.g006
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the ratio of c-jun and AR is affected differently by this agents
and so is also the phosphorylation status of c-jun.
Nevertheless the immunohistochemistry of tumors harvested
failed to show a major phosphorylation of c-jun which we
observed in our in vitro studies, although p-cjun expression
pattern differed in Pac treated tumors in being more distinct
localized to the nucleus. The same was also true for the AR
pattern as seen in Figure 6. However, the growth curves in
Pac/bic and Doc/bic treated mice differed markedly which
supports our hypothesis that c-jun acts as a potent
antiapoptotic factor even in our in vivo model. The xenograft
model shows also clearly that the combined treatment of
taxane and bicalutamide does not improve the outcome of
therapy rendering the proposed model of AR entrapment by
taxane therapy incomplete [6].
Further work is warranted to investigate all phophorylation
sites of c-jun and their interaction with AR to further elucidate
taxane specific effects observed in this study as suggested by
Weiss et al who has shown that c-jun is under control of
repressors which are released upon phosphorylation [15].
Taken together c-jun and AR interaction is enhanced by
taxane therapy. Androgen receptor was translocated by both
taxanes to the cytoplasm (se Figure 6D). The phophorylation of
c-jun is not only linked to JNK pathway and occurs in the early
phase of taxane treatment by yet undefined mechanism. In
castration resistant prostate cancer cells Doc therapy
upregulates AR whereas Pac decreases AR. However, PSA
expression was decreased in both taxanes, indicating that c-jun
was able to repress PSA promoter independent on the taxane
used in hormone refractory prostate cancer cells. Given the
fact that taxane responders in clinical practice are yet defined
by PSA decrease (<50%) one should consider that this might
not reflect the true AR receptor activation in the patient.
Supporting Information
Figure S1.  Western blotting analysis showing AR
translocation to cytoplasm in LNCaP cells treated with Doc
(upper panel) and Pac (lower panel).
(TIF)
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